QuickView for Atenolol (compound)

Summary
General Info

PubChem

PubChem Compound 175540

Name:	Atenolol
PubChem Compound ID:	175540
Description:	A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
Molecular formula:	C₁₄H₂₂N₂O₃
Molecular weight:	266.336 g/mol
Synonyms:	(S)-4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; S-Atenolol; CAS-56715-13-0; (-)-Atenolol; EU-0100156; Lopac-A-7655; Tocris-0393; S-(-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; NCGC00015007-02; NCGC00015007-01. show more » (S)-4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; S-Atenolol; CAS-56715-13-0; (-)-Atenolol; EU-0100156; Lopac-A-7655; Tocris-0393; S-(-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; NCGC00015007-02; NCGC00015007-01; Lopac-A-143; NCGC00015007-03; Lopac-A-142; Tocris-0387; NCGC00024566-01; NCGC00024570-01; 2-(p-((2S)-2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; D01471; Esatenolol; Esatenolol (JAN); CAS-93379-54-5; NCGC00016880-02; SPBio_002472; NCGC00016880-01; Benzeneacetamide, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, (S)-; Prestwick0_000536; 93379-54-5; Prestwick1_000536 show less «

DrugBank

Identification

Name:	Atenolol
Name (isomeric):	DB00335
Drug Type:	small molecule
Description:	A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
Brand:	Aterol, Atenolin, Juvental, Atenol PB, Serten, Atenol Cophar, Atehexal, Atenol Gador, Uniloc, Atenol NM Pharma, Lotenal, Atcardil, Wesipin, Vericordin, Anselol, Tenolol, Betablok, Tenormin, Normalol, Atenet, Jenatenol, Duratenol, Atenol Trom, Stermin, Ateni, Corotenol, Premorine, Atenol Heumann, Evitocor, Hipres, Tensimin, Alinor, Atenol Quesada, Ormidol, Atenol MSD, Tenidon, Atenol Nordic, Atenol 1A Pharma, Tredol, Atenomel, Atenol-Ratiopharm, Scheinpharm Atenol, Altol, Betasyn, Aircrit, Atenblock, Atenol Fecofar, Blocotenol, Oraday, Prenormine, Blokium, Noten, Atenol-Wolff, Atecard, Tenobloc, Atenol Stada, Betatop GE, Normiten, Atenil, Loten, Atenol Genericon, Internolol, Atenol AL, Farnormin, Vascoten, Lo-Ten, Cuxanorm, Panapres, Atenol Von CT, Plenacor, Atenol Acis, Servitenol, Apo-Atenolol, Hypoten, Cardiopress, Teno-Basan, Seles Beta, Xaten, Selobloc, Atereal, Myocord, Cardaxen, Antipressan, Prenolol, Atenol CT, Tenoprin, Betacard, Ibinolo, Atenol Atid, Duraatenolol, Tenormine, Atenol-Mepha, Atenol Tika, Atendol, Felo-Bits, Unibloc, Tenoblock, Atenol, Prinorm, Atenol GNR
Brand name mixture:	Tenoretic(atenolol + chlorthalidone)
Category:	Sympatholytics, Adrenergic Agents, Antiarrhythmic Agents, Adrenergic beta-Antagonists, Anti-Arrhythmia Agents, Antihypertensive Agents
CAS number:	29122-68-7

Pharmacology

Indication:	For the management of hypertention and long-term management of patients with angina pectoris
Pharmacology:	Atenolol, a competitive beta(1)-selective adrenergic antagonist, has the lowest lipid solubility of this drug class. Although it is similar to metoprolol, atenolol differs from pindolol and propranolol in that it does not have intrinsic sympathomimetic properties or membrane-stabilizing activity. Atenolol is used alone or with chlorthalidone in the... show more » Atenolol, a competitive beta(1)-selective adrenergic antagonist, has the lowest lipid solubility of this drug class. Although it is similar to metoprolol, atenolol differs from pindolol and propranolol in that it does not have intrinsic sympathomimetic properties or membrane-stabilizing activity. Atenolol is used alone or with chlorthalidone in the management of hypertension and edema. show less «
Mechanism of Action:	Like metoprolol, atenolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hyp... show more » Like metoprolol, atenolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension. Higher doses of atenolol also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles. show less «
Absorption:	Approximately 50% of an oral dose is absorbed from the gastrointestinal tract, the remainder being excreted unchanged in the feces.
Protein binding:	Plasma protein binding is 6-16%
Biotransformation:	Hepatic (minimal)
Route of elimination:	Approximately 50% of an oral dose is absorbed from the gastrointestinal tract, the remainder being excreted unchanged in the feces. Unlike propranolol or metoprolol, but like nadolol, atenolol undergoes little or no metabolism by the liver, and the absorbed portion is eliminated primarily by renal excretion.
Half Life:	6-7 hours
Toxicity:	LD₅₀=2000-3000 mg/kg(orally in mice). Symptoms of an atenolol overdose include a slow heart beat, shortness of breath, fainting, dizziness, weakness, confusion, nausea, and vomiting.
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Consult your doctor before taking large amounts of Vitamin K (Green leafy vegetables).

Take 30-60 minutes before meals, take at the same time each day.

Drug interaction:

Ibuprofen	Risk of inhibition of renal prostaglandins
Ergotamine	Ischemia with risk of gangrene
Procaterol	Antagonism
Epinephrine	Hypertension, then bradycardia
Terazosin	Increased risk of hypotension. Initiate concomitant therapy cautiously.

Ibuprofen	Risk of inhibition of renal prostaglandins
Ergotamine	Ischemia with risk of gangrene
Procaterol	Antagonism
Epinephrine	Hypertension, then bradycardia
Terazosin	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Clonidine	Increased hypertension when clonidine stopped
Insulin Glargine	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Salmeterol	Antagonism
Glycodiazine	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Glisoxepide	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Glipizide	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Insulin Aspart	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Terbutaline	Antagonism
Methysergide	Ischemia with risk of gangrene
Gliclazide	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Tolazamide	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Insulin	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Treprostinil	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Repaglinide	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Salbutamol	Antagonism
Insulin Glulisine	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Fenoterol	Antagonism
Tolbutamide	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Pipobroman	Antagonism
Orciprenaline	Antagonism
Formoterol	Antagonism
Dihydroergotamine	Ischemia with risk of gangrene
Acetohexamide	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Chlorpropamide	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Disopyramide	The beta-blocker, atenolol, may increase the toxicity of disopyramide.
Diltiazem	Increased risk of bradycardia
Dihydroergotoxine	Ischemia with risk of gangrene
Ampicillin	Ampicillin decreases bioavailability of atenolol
Isoproterenol	Antagonism
Verapamil	Increased effect of both drugs
Insulin Detemir	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Pirbuterol	Antagonism
Insulin Lispro	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Lidocaine	The beta-blocker, atenolol, may increase the effect and toxicity of lidocaine.
Prazosin	Risk of hypotension at the beginning of therapy
Piroxicam	Risk of inhibition of renal prostaglandins
Glyburide	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
Indomethacin	Risk of inhibition of renal prostaglandins
Ergonovine	Ischmeia with risk of gangrene

show less «

Targets

Beta-1 adrenergic receptor

Transporters

Multidrug resistance protein 1